novolakit
Novolakit is a synthetic anti-inflammatory agent first developed in the early 2010s by the pharmaceutical research group at MedicaPharm Laboratories. The compound is a modified derivative of the non-steroidal anti-inflammatory drug (NSAID) class, featuring a novel carbonyl‑substituted scaffold that enhances selectivity for the cyclooxygenase‑2 (COX‑2) enzyme while reducing gastric toxicity. Its chemical formula is C19H16N2O4, and it is available in oral tablet form at a typical dose of 150 mg twice daily.
Clinical trials conducted between 2014 and 2018 demonstrated that Novolakit reduces pain and swelling in patients
Novolakit has not yet been approved by the U.S. Food and Drug Administration (FDA) or the European